Prosecution Insights
Prosecution Insights
11 pending office actions • 7 clients • 10 examiners • 8 art units • 0 of 11 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 11 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 11 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (18%) |
| §102 only | 3 (27%) |
| §112 only | 2 (18%) |
| No statute on record | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BOYLE, ROBERT C | 2 | 69.4% | -2.6% |
| SAIDHA, TEKCHAND | 1 | 82.9% | +13.9% |
| HOWELL, THEODORE R | 1 | 66.8% | +25.4% |
| CHEN, STACY BROWN | 1 | 65.9% | +40.1% |
| MOU, LIYUAN | 1 | 43.2% | +58.1% |
| OUSPENSKI, ILIA I | 1 | 77.6% | +20.3% |
| PHAM, TUAN A | 1 | 83.6% | +27.1% |
| MILLER, DALE R | 1 | 62.3% | +16.5% |
| LI, BAO Q | 1 | 75.9% | +26.2% |
| SKELDING, ZACHARY S | 1 | 59.9% | +41.5% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17918882 | SYSTEM AND METHOD FOR PROFILING ANTIBODIES WITH HIGH-CONTENT SCREENING (HCS) | PHAM, TUAN A | 19d overdue |
| 18273261 | ACYL ACTIVATING ENZYMES FOR PREPARATION OF CANNABINOIDS | SAIDHA, TEKCHAND | 1d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038673 | YEAST-BASED EXPRESSION OF THERAPEUTIC PROTEINS IN VIVO | CHEN, STACY BROWN | 78d overdue |
| 18121557 | INTESTINAL EXPRESSION OF PROGRAMMED DEATH LIGAND 1 | OUSPENSKI, ILIA I | 60d overdue |
| 18033187 | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS | MOU, LIYUAN | 45d overdue |
| 18212115 | Dissolved Protein Arthritis Markers | HOWELL, THEODORE R | 31d overdue |
| 17918882 | SYSTEM AND METHOD FOR PROFILING ANTIBODIES WITH HIGH-CONTENT SCREENING (HCS) | PHAM, TUAN A | 19d overdue |
| 17612179 | Yeast-Based Oral Vaccination | LI, BAO Q | 17d overdue |
| 17298903 | METHODS FOR SELECTIVE IN VIVO EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF | SKELDING, ZACHARY S | 2d overdue |
| 18273261 | ACYL ACTIVATING ENZYMES FOR PREPARATION OF CANNABINOIDS | SAIDHA, TEKCHAND | 1d overdue |
| Client (Assignee) | Pending OAs |
|---|---|
| University of British Columbia | 3 |
| ESPEROVAX INC. | 2 |
| ENGENE, INC. | 2 |
| BAYMEDICA, INC. | 1 |
| INMED PHARMACEUTICALS INC. | 1 |
| PHENOMIC AI | 1 |
| ADICET THERAPEUTICS, INC. | 1 |
| Art Unit | Apps |
|---|---|
| 1764 | 2 |
| 1628 | 2 |
| 1644 | 2 |
| 1652 | 1 |
| 1672 | 1 |
| 2163 | 1 |
| 1693 | 1 |
| 1671 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18417258 | NOVEL AMINE FUNCTIONALIZED POLYMERS AND METHODS OF PREPARATION | The University of British Columbia | BOYLE, ROBERT C | 1764 | §102 | Non-Final OA | 36d overdue | Pending | Jan 19, 2024 |
| 18273261 | ACYL ACTIVATING ENZYMES FOR PREPARATION OF CANNABINOIDS | BAYMEDICA, INC. | SAIDHA, TEKCHAND | 1652 | §102 | Non-Final OA | 1d overdue | Pending | Jul 19, 2023 |
| 18268464 | METHODS FOR HYDROAMINOALKYLATION OF OLEFINS AND GROUP 4 METAL COMPLEXES USEFUL IN SUCH METHODS | The University of British Columbia | BOYLE, ROBERT C | 1764 | §102 | Non-Final OA | 8d | Pending | Jun 20, 2023 |
| 18212115 | Dissolved Protein Arthritis Markers | The University of British Columbia | HOWELL, THEODORE R | 1628 | Other | Non-Final OA | 31d overdue | Pending | Jun 20, 2023 |
| 18038673 | YEAST-BASED EXPRESSION OF THERAPEUTIC PROTEINS IN VIVO | Esperovax Inc. | CHEN, STACY BROWN | 1672 | Other | Non-Final OA | 78d overdue | Pending | May 24, 2023 |
| 18033187 | COMPOSITIONS AND METHODS FOR TREATING NEURONAL DISORDERS WITH CANNABINOIDS | Inmed Pharmaceuticals Inc. | MOU, LIYUAN | 1628 | §103 | Non-Final OA | 45d overdue | Pending | Apr 21, 2023 |
| 18121557 | INTESTINAL EXPRESSION OF PROGRAMMED DEATH LIGAND 1 | Engene, Inc. | OUSPENSKI, ILIA I | 1644 | Other | Non-Final OA | 60d overdue | Pending | Mar 14, 2023 |
| 17918882 | SYSTEM AND METHOD FOR PROFILING ANTIBODIES WITH HIGH-CONTENT SCREENING (HCS) | Phenomic AI | PHAM, TUAN A | 2163 | §103 | Non-Final OA | 19d overdue | Pending | Oct 13, 2022 |
| 17794577 | LOCALIZED EXPRESSION OF THERAPEUTIC NUCLEIC ACIDS IN LUNG EPITHELIAL CELLS | Engene, Inc. | MILLER, DALE R | 1693 | Other | Non-Final OA | 15d | Pending | Jul 21, 2022 |
| 17612179 | Yeast-Based Oral Vaccination | Esperovax Inc. | LI, BAO Q | 1671 | §112 | Final Rejection | 17d overdue | Pending | Nov 17, 2021 |
| 17298903 | METHODS FOR SELECTIVE IN VIVO EXPANSION OF GAMMA DELTA T-CELL POPULATIONS AND COMPOSITIONS THEREOF | Adicet Therapeutics, Inc. | SKELDING, ZACHARY S | 1644 | §112 | Final Rejection | 2d overdue | Pending | Jun 01, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial